Matches in Wikidata for { <http://www.wikidata.org/entity/Q92852993> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- Q92852993 description "article scientifique publié en 2019" @default.
- Q92852993 description "artículu científicu espublizáu en marzu de 2019" @default.
- Q92852993 description "scientific article published on 28 March 2019" @default.
- Q92852993 description "wetenschappelijk artikel" @default.
- Q92852993 description "наукова стаття, опублікована 28 березня 2019" @default.
- Q92852993 name "A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)" @default.
- Q92852993 name "A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)" @default.
- Q92852993 type Item @default.
- Q92852993 label "A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)" @default.
- Q92852993 label "A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)" @default.
- Q92852993 prefLabel "A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)" @default.
- Q92852993 prefLabel "A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)" @default.
- Q92852993 P1433 Q92852993-AC5F6166-BADA-404E-9234-56ADD24B72E0 @default.
- Q92852993 P1476 Q92852993-1436A909-211E-4565-814F-BD75CD347804 @default.
- Q92852993 P2093 Q92852993-0B78E42D-0702-42AE-AEBB-47962D065CC4 @default.
- Q92852993 P2093 Q92852993-15467CA6-37C4-42E8-8260-28775EFAFE33 @default.
- Q92852993 P2093 Q92852993-28FA9A7B-8991-40A0-94CE-3B49741E5FF7 @default.
- Q92852993 P2093 Q92852993-30585964-3E9E-451A-88AE-F3030DC83998 @default.
- Q92852993 P2093 Q92852993-34881862-A842-4DB1-9CA0-2F58CC0A5E73 @default.
- Q92852993 P2093 Q92852993-5BB6F138-E84C-4924-B212-23D352AB5D0D @default.
- Q92852993 P2093 Q92852993-5BEE4CF1-1123-4685-B6D5-BA1532DA4571 @default.
- Q92852993 P2093 Q92852993-64E32701-1A52-49E0-A347-2AC7C19C9A8A @default.
- Q92852993 P2093 Q92852993-69348EA8-D914-4631-99BE-D884E60A304C @default.
- Q92852993 P2093 Q92852993-78A76DFD-DB98-41B1-B36D-DAF288470FFC @default.
- Q92852993 P2093 Q92852993-8D68EA15-7A57-45CB-A54C-52F84F6A515F @default.
- Q92852993 P2093 Q92852993-9245218F-6807-4F43-987C-88E5B743899B @default.
- Q92852993 P2093 Q92852993-9FCABCA7-BEBD-4CD1-959F-6579C8935378 @default.
- Q92852993 P2093 Q92852993-ACA4A060-9028-401F-910F-C4F17AFE578D @default.
- Q92852993 P2093 Q92852993-B071E00B-6ABD-4DEC-A066-774D76C9752D @default.
- Q92852993 P2093 Q92852993-B3DB7D3D-786D-47A1-BDCC-60A709048C0E @default.
- Q92852993 P2093 Q92852993-B9FA9CBC-33B6-4D5D-BDB0-B6DDB34AB1B4 @default.
- Q92852993 P2093 Q92852993-BCA9881D-98FF-48D1-A30B-183A3C9BF666 @default.
- Q92852993 P2093 Q92852993-C26489A2-5FBE-4B87-AB6C-79230752057A @default.
- Q92852993 P2093 Q92852993-C4F89272-E5DA-4FD4-BB0B-2BAF3DAF57A6 @default.
- Q92852993 P2093 Q92852993-E9A95297-B9D7-4764-9613-6B99951BAD1A @default.
- Q92852993 P304 Q92852993-C043635F-55FC-4746-BCE5-A91CD65A84EF @default.
- Q92852993 P31 Q92852993-1CA881EE-6A47-443E-ADBD-417A717A4666 @default.
- Q92852993 P356 Q92852993-86615708-EAC2-4268-AA18-13306F4AFDF3 @default.
- Q92852993 P478 Q92852993-4BFE54FC-2B2A-4FCA-9668-CA8DAC6180CE @default.
- Q92852993 P577 Q92852993-82BE8E89-1F23-4BAD-ADA2-E84AE0A8651F @default.
- Q92852993 P698 Q92852993-16D58447-42D5-4211-9151-5DDCB8ADE17F @default.
- Q92852993 P356 J.LUNGCAN.2019.03.030 @default.
- Q92852993 P698 31446992 @default.
- Q92852993 P1433 Q641464 @default.
- Q92852993 P1476 "A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)" @default.
- Q92852993 P2093 "Chisato Miyakoshi" @default.
- Q92852993 P2093 "Daichi Fujimoto" @default.
- Q92852993 P2093 "Hiroshige Yoshioka" @default.
- Q92852993 P2093 "Katsuya Hirano" @default.
- Q92852993 P2093 "Keisuke Tomii" @default.
- Q92852993 P2093 "Kenichi Yoshimura" @default.
- Q92852993 P2093 "Kyoto Thoracic Oncology Research Group (KTORG)" @default.
- Q92852993 P2093 "Mariko Kogo" @default.
- Q92852993 P2093 "Masataka Hirabayashi" @default.
- Q92852993 P2093 "Masaya Akai" @default.
- Q92852993 P2093 "Ryogo Kagami" @default.
- Q92852993 P2093 "Tadashi Ishida" @default.
- Q92852993 P2093 "Takahiro Kawai" @default.
- Q92852993 P2093 "Takashi Nishimura" @default.
- Q92852993 P2093 "Takehiro Okuno" @default.
- Q92852993 P2093 "Toshihide Yokoyama" @default.
- Q92852993 P2093 "Toyohiro Hirai" @default.
- Q92852993 P2093 "Yasuharu Nakahara" @default.
- Q92852993 P2093 "Yasuyoshi Washio" @default.
- Q92852993 P2093 "Yoshiki Demura" @default.
- Q92852993 P2093 "Young Hak Kim" @default.
- Q92852993 P304 "175-180" @default.
- Q92852993 P31 Q13442814 @default.
- Q92852993 P356 "10.1016/J.LUNGCAN.2019.03.030" @default.
- Q92852993 P478 "135" @default.
- Q92852993 P577 "2019-03-28T00:00:00Z" @default.
- Q92852993 P698 "31446992" @default.